See more : NEXT Biometrics Group ASA (NEXT.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Bioteque Corporation (4107.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bioteque Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Kane Biotech Inc. (KNBIF) Income Statement Analysis – Financial Results
- Rheinmetall AG (RNMBY) Income Statement Analysis – Financial Results
- BactiQuant A/S (BACTIQ.CO) Income Statement Analysis – Financial Results
- Empowerment & Inclusion Capital I Corp. (EPWR) Income Statement Analysis – Financial Results
- Liberty Resources Acquisition Corp. (LIBYW) Income Statement Analysis – Financial Results
Bioteque Corporation (4107.TWO)
About Bioteque Corporation
Bioteque Corporation manufactures and sells medical devices in Asia, South America, North America, and internationally. The company provides medical disposables for use in hemodialysis access, endovascular treatment, and other fields. It also offers dialysis products, including hemodialysis bloodlines, A.V.F. needles, and hemodialysis cathers; interventional radiology products, such as pigtail drainage catheter sets, introducer sets, connecting tubes, drainage bags, and radiopaque dilators; urology products comprising ureteral stent sets and urine collection bags; and IV administration products, such as PVC IV infusion bags, PVC bags, and twist-off ports. In addition, the company provides respiratory care products, such as closed suction catheters and endotracheal tubes; vascular access products comprising angiographic catheters, PTA balloon dilatation catheters, sheath introducers, guidewires, high pressure connecting tubes, PTCA balloon dilatation catheter-rapid exchange products, manifolds, and Y connectors; and medical components, including dialyzer connectors and caps, recirculating connectors with cap, rotating luer lock connectors, pump and T connectors, injection sites, female luers, luer lock and chamber caps, drip chambers, filters, clamps, pressure pillows, safeline HDF components, chamber assembly, and transducer protectors, as well as medical masks. Bioteque Corporation was incorporated in 1991 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.94B | 2.01B | 1.83B | 1.95B | 1.86B | 1.61B | 1.42B | 1.41B | 1.26B | 1.12B | 957.88M | 842.31M | 760.31M | 821.62M | 780.01M | 654.86M | 560.06M | 491.85M |
| Cost of Revenue | 1.13B | 1.17B | 1.02B | 1.10B | 1.04B | 923.97M | 816.55M | 780.98M | 708.72M | 648.50M | 571.84M | 548.16M | 519.94M | 512.61M | 500.55M | 460.94M | 415.40M | 361.67M |
| Gross Profit | 818.94M | 844.54M | 802.87M | 851.75M | 816.96M | 689.04M | 603.67M | 625.98M | 550.70M | 475.17M | 386.05M | 294.14M | 240.38M | 309.01M | 279.46M | 193.93M | 144.66M | 130.18M |
| Gross Profit Ratio | 42.11% | 42.01% | 43.98% | 43.73% | 43.95% | 42.72% | 42.51% | 44.49% | 43.73% | 42.29% | 40.30% | 34.92% | 31.62% | 37.61% | 35.83% | 29.61% | 25.83% | 26.47% |
| Research & Development | 70.44M | 69.98M | 68.83M | 71.82M | 51.47M | 37.96M | 37.77M | 55.69M | 53.88M | 52.51M | 45.86M | 45.36M | 47.29M | 41.53M | 34.99M | 30.94M | 23.47M | 16.44M |
| General & Administrative | 91.22M | 89.39M | 83.66M | 86.91M | 96.33M | 85.90M | 76.51M | 75.89M | 71.72M | 65.74M | 50.17M | 44.35M | 38.02M | 37.19M | 40.19M | 33.52M | 25.44M | 25.63M |
| Selling & Marketing | 77.10M | 106.80M | 102.45M | 86.14M | 88.66M | 75.99M | 61.22M | 55.70M | 56.87M | 58.61M | 53.55M | 49.50M | 49.25M | 55.67M | 48.89M | 44.17M | 45.18M | 38.16M |
| SG&A | 168.32M | 196.19M | 186.11M | 173.05M | 184.99M | 161.89M | 137.73M | 131.59M | 128.60M | 124.34M | 103.72M | 93.86M | 87.27M | 92.86M | 89.08M | 77.68M | 70.62M | 63.79M |
| Other Expenses | 0.00 | 46.99M | -8.56M | -5.98M | 14.02M | 29.03M | -32.27M | 5.38M | 36.01M | 40.95M | 14.72M | 23.37M | 28.20M | 31.42M | 17.36M | 109.49M | -36.60M | 17.27M |
| Operating Expenses | 238.76M | 266.17M | 254.94M | 244.87M | 236.47M | 199.85M | 175.50M | 187.28M | 182.48M | 176.85M | 149.58M | 139.22M | 134.56M | 134.39M | 124.06M | 108.62M | 94.09M | 80.23M |
| Cost & Expenses | 1.36B | 1.43B | 1.28B | 1.34B | 1.28B | 1.12B | 992.05M | 968.26M | 891.20M | 825.35M | 721.42M | 687.38M | 654.49M | 647.01M | 624.62M | 569.56M | 509.49M | 441.90M |
| Interest Income | 10.97M | 2.14M | 729.00K | 2.31M | 5.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.70M | 5.79M | 4.21M | 5.49M | 12.79M | 14.07M | 1.14M |
| Interest Expense | 11.60M | 4.32M | 1.90M | 1.25M | 1.93M | 2.96M | 2.83M | 3.37M | 3.57M | 2.83M | 2.48M | 2.95M | 3.46M | 3.23M | 2.64M | 6.31M | 11.30M | 9.81M |
| Depreciation & Amortization | 155.96M | 131.63M | 122.20M | 111.72M | 96.13M | 85.91M | 75.96M | 73.35M | 72.92M | 66.41M | 68.30M | 65.52M | 61.43M | 55.81M | 49.83M | 33.93M | 39.07M | 46.73M |
| EBITDA | 737.08M | 759.13M | 662.30M | 714.93M | 690.64M | 604.14M | 471.86M | 517.43M | 441.14M | 405.67M | 304.76M | 290.17M | 204.32M | 256.94M | 225.77M | 226.37M | 460.46M | 118.24M |
| EBITDA Ratio | 37.90% | 37.76% | 36.28% | 36.71% | 37.15% | 37.45% | 33.44% | 37.08% | 37.89% | 36.10% | 33.35% | 29.79% | 26.69% | 31.15% | 28.77% | 35.44% | 10.80% | 23.29% |
| Operating Income | 580.18M | 627.50M | 540.09M | 603.21M | 594.50M | 489.19M | 428.17M | 438.70M | 368.22M | 298.32M | 236.47M | 154.93M | 105.82M | 174.62M | 155.40M | 85.30M | 50.57M | 49.95M |
| Operating Income Ratio | 29.83% | 31.21% | 29.59% | 30.97% | 31.98% | 30.33% | 30.15% | 31.18% | 29.24% | 26.55% | 24.69% | 18.39% | 13.92% | 21.25% | 19.92% | 13.03% | 9.03% | 10.16% |
| Total Other Income/Expenses | -10.66M | 44.80M | -9.73M | -5.09M | 12.08M | 26.08M | -35.10M | 2.01M | 32.44M | 38.12M | 12.24M | 38.95M | 33.61M | 23.29M | 17.91M | 100.84M | 359.51M | 11.84M |
| Income Before Tax | 569.52M | 623.18M | 538.20M | 601.79M | 592.57M | 515.27M | 393.07M | 440.71M | 400.66M | 336.44M | 248.71M | 193.87M | 139.43M | 197.90M | 173.31M | 186.14M | 410.09M | 61.79M |
| Income Before Tax Ratio | 29.29% | 31.00% | 29.48% | 30.90% | 31.88% | 31.94% | 27.68% | 31.32% | 31.81% | 29.94% | 25.96% | 23.02% | 18.34% | 24.09% | 22.22% | 28.42% | 73.22% | 12.56% |
| Income Tax Expense | 116.97M | 129.64M | 106.94M | 113.13M | 128.40M | 110.27M | 89.13M | 82.48M | 84.89M | 45.54M | 33.48M | 27.57M | 10.83M | 25.32M | 14.79M | 14.69M | 100.94M | 4.53M |
| Net Income | 452.55M | 493.54M | 431.26M | 488.67M | 464.17M | 405.00M | 303.94M | 358.23M | 315.77M | 290.90M | 215.22M | 166.31M | 128.60M | 172.59M | 158.52M | 171.46M | 309.15M | 57.27M |
| Net Income Ratio | 23.27% | 24.55% | 23.62% | 25.09% | 24.97% | 25.11% | 21.40% | 25.46% | 25.07% | 25.89% | 22.47% | 19.74% | 16.91% | 21.01% | 20.32% | 26.18% | 55.20% | 11.64% |
| EPS | 6.53 | 7.12 | 6.22 | 7.05 | 6.70 | 5.84 | 4.39 | 5.17 | 4.07 | 3.43 | 2.71 | 2.13 | 1.62 | 2.17 | 2.00 | 2.17 | 4.14 | 0.91 |
| EPS Diluted | 6.50 | 7.09 | 6.20 | 7.02 | 6.67 | 5.81 | 4.37 | 5.14 | 4.03 | 3.34 | 2.67 | 2.11 | 1.61 | 2.16 | 1.98 | 2.15 | 3.92 | 0.75 |
| Weighted Avg Shares Out | 69.30M | 69.30M | 69.30M | 69.30M | 69.30M | 69.30M | 69.30M | 69.29M | 77.56M | 84.83M | 79.42M | 78.28M | 79.32M | 79.32M | 79.32M | 79.18M | 74.69M | 62.92M |
| Weighted Avg Shares Out (Dil) | 69.62M | 69.65M | 69.60M | 69.59M | 69.60M | 69.65M | 69.58M | 69.66M | 78.50M | 87.43M | 80.63M | 78.89M | 80.14M | 79.78M | 79.85M | 79.89M | 78.89M | 76.63M |
Source: https://incomestatements.info
Category: Stock Reports